ACRS peer analysis
Aclaris Therapeutics (ACRS) against its competitors: price, today's move, 1-year return and market value side by side.
ACRS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AGMB AgomAb | $6.97 | 1.75% | – | – |
| ALDX Aldeyra Therapeutics | $0.62 | -4.87% | -87.51% | $37.16M |
| ALMS Alumis | $6.03 | 3.08% | 31.51% | – |
| ANAB AnaptysBio | $45.80 | 0.48% | 29.08% | $1.39B |
| ATTO Attovia Therapeutics | $15.27 | 1.80% | – | $694.81M |
| IFRX InflaRx | $1.30 | -3.69% | 5.24% | $19.43M |
| IMUX Immunic | $7.64 | 4.37% | 7.35% | $105.88M |
| MLTX MoonLake | $11.60 | 7.41% | 9.07% | – |
| ODTX Odyssey Therapeutics | $19.23 | 1.85% | – | – |
| TRAX First Tracks Biotherapeutics | $49.00 | 7.86% | – | – |
| ACRS Aclaris Therapeutics | $3.90 | 8.03% | 59.73% | $504.77M |
- ACRS's peers: AGMB (AgomAb), ALDX (Aldeyra Therapeutics), ALMS (Alumis), ANAB (AnaptysBio), ATTO (Attovia Therapeutics), IFRX (InflaRx), IMUX (Immunic), MLTX (MoonLake).
Updated 2026-11-07 11:55 UTC